Your puppy looks fine. Your puppy acts fine and there is not a single sign that three years from now, he might develop cancer.
Many pet parents worry about their dog’s future health, but they delay them. They delay genetic testing because they are optimistic.
A young, visibly healthy, and full of energy puppy is not something you should worry about. At least that is the idea. But the problem with that logic is misunderstanding what genetic testing measures.
You Might Wait, But the Disease Does Not.
Timing is precious when it comes to preventing and reacting to disease. Testing helps you react on time.
According to a large study of more than 28,000 canines in Croatia, examining dogs over a period of 14 years, canine lymphoma typically strikes between ages five and ten. Most dogs get diagnosed by age eight. That means most pet parents miss three years where they could have acted.
Another study, by the Animal Cancer Registry in 2024, showed that the median age at diagnosis for malignant tumors was 9 to 10 years. And most dogs developed cancer long before the diagnosis.
The picture is clear. The American Veterinary Medical Association tells us that one in four dogs will develop cancer over their lifetime. That number goes up in dogs over ten years of age.
What does that mean for your young puppy? In simple terms, a puppy tested for cancer risk at twelve months of age, has between five and eight years before the highest-risk window opens. That means five to eight years of preventive monitoring, targeted checkups, diet plans, and proactive veterinary strategy.
And if that result adds two to three more years for your dog, the test has more than paid its price.
For comparison, a dog tested at seven years, has only a fraction of that timeframe for reacting.
Early Treatment = Better Survival Rate
This is more than theory. Studies prove that testing early results in better lifespan for dogs. The PROTECT study, a randomized, placebo-controlled trial published in the Journal of Veterinary Internal Medicine, shows it.
The study examined what happens when dogs with preclinical dilated cardiomyopathy receive treatment before the symptoms appear. The results? Dogs treated before symptoms have a median survival of 623 days, compared to 466 days in the placebo group, and reached heart failure a median of 277 days later than untreated dogs.
Neither dog showed symptoms. Neither dog was in a crisis situation. But all of them were at risk, and when someone acted early, the results showed a positive trend.
The results are similar when it comes to cancer. AKC Canine Health Foundation’s research on hemangiosarcoma, which is one of the six cancers in the SmartDx panel, found that early detection and targeted treatment can raise the one-year survival rate from 15% to 40%. That is not a marginal improvement. That is almost three times better chances of survival.
SmartDx’s panel cannot detect cancer early. What it can do is show whether your dog has a risk of developing cancer. And if you react early, when your puppy is still young, that gives you more than enough time to prevent it. Or in the worst case, postpone it so that your young and lively puppy can reach its golden years.
Dogs identified at risk before disease develops have access to interventions, monitoring schedules, and treatment windows that simply don’t exist for dogs who arrive symptomatic.
What Does the SmartDx Test measure?
The SmartDx tests start with an oral swab. You take one at your home, and send it for testing. Your dog’s DNA then goes through two systems.
The first one is MORSE, which converts the raw genomic sequencing data into a binary format that the next system can analyze.
The second one is MEW, a semi-supervised AI algorithm that performs lifetime disease risk assessment. The models were trained on data from more than 2,500 dogs diagnosed at advanced ages and more than 14,000 undiagnosed dogs.
The result checks for nine conditions, six cancers, including the common ones like lymphoma and mammary tumors, and three cardiac diseases.
For each condition, the test returns one of three results. “Not at risk” means Mew found no increased risk in your dog’s genetic profile for that condition. “At risk” means the algorithm has flagged an elevated risk. “Uncertain” means Mew puts the probability at roughly 50 percent, neither clearly elevated nor clear. A coin flip, and one that should prompt continued monitoring.
The Test Result Will Not Change Tomorrow or One Year After
For some pet parents, waiting is not a conscious decision. It is the absence of one, a quiet agreement to stay in the uncertainty rather than get a result that might change everything.
But the problem with that logic is that your dog’s genetic profile will not change. It is what it is, today, tomorrow, a month from now, a year from now. If the result returns “at risk”, that doesn’t mean your dog has cancer.
An “at risk” result is Mew’s prediction that your dog may develop that condition. That is not a confirmation that your dog will develop cancer. Mev is an AI, and like many AI systems, it can make mistakes. The result provides a match against a database of diseased dogs.
Mew has evaluated your dog’s genetic sequence using patterns it learned from training on thousands of canine sequences, some carrying disease labels, some not. The model does not compare your dog’s profile against known diseased cases. The result reflects the algorithm’s overall judgment, a pattern it has learned to recognize, not a direct match to a diagnosed dog.
That data is the earliest possible and useful signal for you to be proactive. This result comes years before there is anything visible to treat.
You can have that information right now, and act accordingly. The DNA is readable and available now. Pet parents can check with their current provider if they offer SmartDx digital upgrades. The only thing that delays the information is your decision to wait.
That decision has one outcome: fewer months on the right side of a diagnosis. Even if your dog looks healthy and acts healthy, there is no age too young to test.
There is no Benefit in Waiting
There is no version of the test where waiting delay improves the outcome. Your puppy’s DNA will remain the same at age three, five, eight, or ten years old.
What does change with time is the number of veterinary visits during which you can establish preventive protocols. The number of months that a high-risk dog spent unmonitored.
There are plenty of treatment options during early-stage disease. Fewer of them are available once dogs reach a critical stage.
SmartDx was built on the idea that knowing early gives you real choices. Waiting removes those choices, one month at a time.